Objective: To assess the cost-effectiveness of introducing pneumococcal polysaccharide and nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in the National Immunization Programme of Malaysia. This study compared introducing PHiD-CV (10 valent vaccine) with current no vaccination, as well as against the alternative 13-valent pneumococcal conjugate vaccine (PCV13). Methods: A lifetime Markov cohort model was adapted using national estimates of disease burden, outcomes of pneumococcal disease, and treatment costs of disease manifestations including pneumonia, acute otitis media, septicemia, and meningitis for a hypothetical birth cohort of 550,000 infants. Clinical information was obtained by review of medical records from four public hospitals in Malaysia from the year 2008 to 2009. Inpatient cost from the four study hospitals was obtained from a diagnostic-related group-based costing system. Outpatient cost was estimated using clinical pathways developed by an expert panel. The perspective assessed was that of the Ministry of Health, Malaysia. Results: The estimated disease incidence was 1.2, 3.7, 70, and 6.9 per 100,000 population for meningitis, bacteremia, pneumonia, and acute otitis media, respectively. The Markov model predicted medical costs of Malaysian ringgit (RM) 4.86 billion (US $1.51 billion) in the absence of vaccination. Vaccination with PHiD-CV would be highly cost-effective against no vaccination at RM30,290 (US $7,407) per quality-adjusted life-year gained. On comparing PHiD-CV with PCV13, it was found that PHiD-CV dominates PCV13, with 179 quality-adjusted life-years gained while saving RM35 million (US $10.87 million). Conclusions: It is cost-effective to incorporate pneumococcal vaccination in the National Immunization Programme of Malaysia. Our model suggests that PHiD-CV would be more cost saving than PCV13 from the perspective of the Ministry of Health of Malaysia.
Introduction
In Malaysia, an upper-middle-income developing country, vaccines have played an important role toward improving health outcomes of the population over the past five decades. The country began vaccinating against important childhood diseases in the 1960s. Health services afforded mostly by the government have helped Malaysia to establish a low infant mortality rate of 6.3 per 1000 live births and a maternal mortality rate of 0.3 per 1000 live births [1] [2] [3] . Currently, the National Immunization Programme (NIP) covers many of the main childhood diseases: diphtheria, pertussis, tetanus, tuberculosis, poliomyelitis, measles, mumps, rubella, Haemophilus influenzae b, and hepatitis B [4] .
Lack of data on pneumococcal disease in Malaysia has been cited as the main reason for not including the pneumococcal vaccine in the NIP [5] . One of the reasons in Malaysia, as in many developing countries, is the lack of ability to confirm the causative pneumococcal pathogen. Emerging new evidence, however, points to the benefit of pneumococcal vaccination [6, 7] .
Globally, Streptococcus pneumoniae (S. pneumoniae) has already been established as one of the leading causes of vaccinepreventable diseases and deaths among children younger than 5 years [8] . Many countries have begun to address this issue by providing pneumococcal vaccination as part of their vaccination programs, including the United States, Australia, the United Kingdom, Norway, Japan, as well as Colombia [9] [10] [11] [12] [13] [14] . Several conjugate vaccines are available as options for pneumococcal vaccination, including the 7-valent pneumococcal conjugate vaccine (PCV7), pneumococcal polysaccharide and nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV), and the 13-valent pneumococcal conjugate vaccine (PCV13). The result of cost-effectiveness studies between PHiD-CV and PCV13 in different countries varies depending on the outcome of interest and country-specific input data parameters. An earlier study showed that the PCV7 vaccine would be cost-effective for Malaysia as compared with no vaccination, with an incremental cost-effectiveness ratio (ICER) of Malaysian ringgit (RM) 35,196 (US $10,261) per life-year gained based on 2007 prices, which would be well below the World Health Organization threshold for Malaysia, which was RM71,761 (US $20,922) [7] . The costeffectiveness of the other available pneumococcal vaccines, however, has not been evaluated locally.
The objective of this study was to assess the costeffectiveness of introducing PHiD-CV in the NIP of Malaysia. This study compares introducing PHiD-CV (10 valent vaccine) with current no vaccination, as well as against the alternative 13 valent vaccine (PCV13).
Methods
Using Malaysian epidemiological data, clinical outcome, and cost inputs, we adapted a Markov cohort model developed by Knerer et al. [15] . The model was static, deterministic, and compartmentalized by age. The health states built into the model are shown in Fig. 1 . The model simulated the health and cost effects of vaccination in a birth cohort of 550,000 infants followed in monthly cycles up to 100 years. A monthly cycle duration was applied to simulate the nature of infections whereby the cohort could be exposed to repeated infections over a relatively short period of time. Half-cycle correction was not applied because of the short cycle duration. Within the model, three disease types Fig. 1 -Markov cohort model. The cohort model is Markov based, with three exclusive health states: no disease, sequelae, and death. The transition from "no" disease to "sequelae" or "death" is calculated on the basis of this decision tree. In the model, pneumonia has only short-term sequelae whereas meningitis can lead to long-term sequelae; meningitis and bacteremia include NTHi meningitis and NTHi bacteremia, respectively; and nonconsulting AOM are accounted for in the quality-of-life impact calculation. AOM, acute otitis media; GP, general practitioner; PCP, primary care physician; NTHi, nontypeable Haemophilus influenzae.
were modeled, including, invasive pneumococcal diseases (IPDs) (meningitis and bacteremia), community-acquired pneumonia, and acute otitis media (AOM). The model also incorporated pneumonia caused by S. pneumoniae or nontypeable Haemophilus influenzae (NTHi). The analysis was performed from the payer perspective (Ministry of Health, Malaysia).
This study was approved by the ethics committees of the Universiti Kebangsaan Malaysia (UKM) (FF-027-2010) and the Ministry of Health, Malaysia (NMRR-09-1087-4866).
Epidemiology Parameters
Disease incidence was estimated on the basis of a review of medical records from January 1, 2008, to December 1, 2009 , from four tertiary public hospitals from various regions of Malaysia, namely, UKM Medical Centre, Hospital Kuala Lumpur, Hospital Alor Setar, and Hospital Queen Elizabeth, Kota Kinabalu. The four study hospitals were selected to represent various regions of Malaysia.
Inpatient discharge records were used to identify cases of pneumococcal meningitis, bacteremia, pneumonia, and AOM. Cases were primarily identified by using International Statistical Classification of Diseases,10th Revision codes. For the purpose of this study, International Statistical Classification of Diseases,10th Revision pneumococcal disease codes include the following: pneumococcal meningitis (G00.1), bacterial meningitis unspecified (G00.9), pneumococcal septicemia (A40.3), streptococcal septicemia unspecified (A40.9), pneumonia due to S. pneumoniae (J13), other unspecified pneumonia (J15.9, J18, and J18.9), and otitis media (H65, H66, and H66.9). Additional patient-level data for S. pneumoniae culture and sensitivity result were reviewed from laboratory records. All patient-level data were anonymized before analysis.
Estimation of Incident Rates
The estimation of incidence rates was based on the number of cases, stratified by age, identified at the four study hospitals, extrapolated for the catchment population of the respective hospitals. Based on discussions with hospital administrators and clinical experts from the study hospitals, the catchment population for each hospital was assumed to be the entire population within the hospitals' district plus 30% of the state population. The data for district populations, based on year 2010, were obtained from the Department of Statistics, Malaysia. The national incidence rate by age group was adjusted to the year of analysis (2010) and was estimated as the average disease rate across the catchment population of four hospitals. The rates of pneumonia and AOM treated in the outpatient setting in the four study hospitals were assumed to be similar to the ratio of inpatient to outpatient cases in another regional study [16] .
Vaccine Efficacy
The efficacy of PHiD-CV and PCV13 vaccine against invasive forms of pneumococcal disease was determined for all relevant S. pneumoniae serotypes on the basis of data from clinical trials and past studies [17, 18] . Similar to other studies, we incorporated the effect of vaccination on disease caused by NTHi in AOM [12, 14, 15] . The efficacy data of PHiD-CV and PCV13 against pneumonia, IPD due to NTHi, and AOM were obtained from past studies [19] [20] [21] (Table 1) . The model took into account serotype distribution in Malaysia following the results of a local study [6] (see Appendix 1 in Supplemental Materials found at http://dx.doi. org/10.1016/j.vhri.2014.04.008. The effects of serotype and pathogen replacement were also included by assuming reductions in efficacy (negative efficacy) toward serotypes of S. pneumoniae and NTHi that were not protected by the vaccines (Table 1) .
Vaccination was assumed to be administered in a 3 þ 1 dosing regimen for both PHiD-CV and PCV13 given at 2, 3, 4, and 13 months, respectively. To reduce model complexity, all infants were assumed to have received the complete 3 þ 1 course of vaccination. The vaccine coverage was assumed to be 95%, consistent with previous implementation of vaccine programs in Malaysia [4] . Similar to Knerer et al.'s study [15] , the vaccine efficacy rate is assumed to achieve a full efficacy at the last dose at 13 months, and maintain full efficacy until age 3 years, with a fixed linear waning period applied until the age of 10 years. The effect of herd or indirect protection effects in the unvaccinated population was incorporated into the model. Following Knerer et al., we assumed that vaccination with PHiD-CV and PCV13 has a net indirect effect resulting in a 15.4% reduction in IPD in those younger than 5 years and 29% in those aged 5 years or older.
Quality of Life
Lifetime utility weights of quality of life (QOL) and disease types were applied to the model to calculate quality-adjusted life-years (QALYs) gained. The model incorporated disutility resulting from the long-term sequelae of IPD as well as temporary reductions in QOL arising from each episode of the disease of interest, with greater reductions in QOL due to more severe disease. We used an approach similar to that of Knerer et al. and applied utility weights from other populations in our analysis because these data were not available from the local setting. [22] [23] [24] [25] (Table 1) . Average lifetime QOL was assumed to be 0.83 out of 1.0 (where 1.0 was perfect health) in the analysis data from the United Kingdom [26] .
Estimation of Costs
The study incorporates costs of direct medical resources incurred by the Ministry of Health for the treatment of an episode of pneumococcal disease. Costs incurred by patients, such as outof-pocket expenses, were excluded in the study.
Outpatient treatment costs included the cost of physician consultation, drugs, and diagnostic test resources used during preadmission and postdischarge visits to the outpatient department. Resource utilization during visits was estimated from clinical pathways developed with the help of an expert panel group and varied depending on the disease type. Costs of outpatient treatments that were not linked to hospital admission were excluded.
The cost of each episode of hospitalization was calculated as the cost per day of hospitalization in each of the four study hospitals multiplied by the duration of stay. Hospitalization cost included the cost of physician consultation and other human resources, drugs and supplies, equipment, tests, surgeries, and utilities. Costs varied by the type of admission based on their diagnosis using a diagnosis-related group system developed by the United Nations University International and the National University of Malaysia. The cost of each diagnosis-related group at the four study hospitals was estimated by top-down costing using the Clinical Costing Modelling Software (Version 1.0), which distributes costs into three different cost center levels according to allocation factors (e.g., floor area, staff counts, and patient counts). [7, 27] . The following conventions were used for imputing capital and recurrent costs incurred during hospitalization.
Capital cost
The life span of equipment and vehicles was assumed at 5 years, with an annual depreciation of 5%. Only areas and vehicles used within the activity scope of this study were considered. Building cost was not included. 
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Recurrent cost
Recurrent costs included the cost of labor and supplies. Labor costs included salaries, bonuses, and allowances to health care personnel. Cost of supplies was calculated as the total cost of all purchases of medication and nonmedication items. Utility costs due to water, electricity supply, telephone, and waste maintenance were calculated for each activity within the scope of the study. All costs were calculated in Malaysian ringgit (RM) for the year 2010 (US $1 ¼ RM3.22) [28] .
Cost-Effectiveness Analysis
The model was used to estimate the effect of (1) PHiD-CV compared with no vaccination and (2) PHID-CV compared with PCV13 in a birth cohort of 550,000 infants over a 100-year time horizon. Other inputs and assumptions are described in Table 1 and in Appendices 2, 3, 4, and 5 in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2014.04.008.
Cost-effectiveness was expressed as cost per life-year gained (LYG) and cost per QALY gained. LYG was determined by taking into consideration the average life expectancy minus the age of death due to disease (LYG ¼ average life expectancy -age of expected death). QALY gained was calculated in a similar manner using QALY instead of life-years. All costs and outcomes were discounted at 5% per annum in the base-case analysis. On the basis of the recommendation by the World Health Organization, we assume a cost-effectiveness threshold for health interventions of less than three times the per-capita gross domestic product (GDP) [29] .
One-way sensitivity analyses were carried out for the basecase scenario of PHiD-CV 3 þ 1 vaccination program versus no vaccination and PHiD-CV 3 þ 1 vaccination program versus PCV13 3 þ 1 vaccination program. The sensitivity analysis was performed by varying variables by Ϯ20% from their base-case value. The results of sensitivity analyses were shown as tornado diagrams for the 10 variables with the highest differences.
Results

Burden of Disease
The incidence rate was 1.2 per 100,000 population for meningitis, 3.7 per 100,000 for bacteremia, 70 per 100,000 for pneumonia, and 6.9 per 100,000 for AOM. Age-specific incidence rates are provided in Appendices 3, 4, and 5 in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2014.04.008. This is translated into 2,331,202 pneumococcal cases (98% outpatient, 2% inpatient) annually. The total cost of pneumococcal disease without vaccination is estimated to be RM1402 million (US $435.6 million); the estimated cost of meningitis is RM3.7 million (US $1.2 million); bacteremia, RM28 million (US $8.6 million); pneumonia, RM704 million (US $218.5 million); and AOM, RM667 million (US $207.3 million) ( Table 2 ).
Our analysis showed that vaccination reduces deaths and hospitalizations due to meningitis, bacteremia, pneumonia, and AOM. Vaccinating with PHiD-CV or PCV13 produces a similar reduction in the rates of meningitis, bacteremia, and pneumonia. PHiD-CV vaccination, however, results in much fewer cases of hospitalized myringotomy and outpatient AOM than does PCV13 (Table 3 ). The modeling analysis shows that PHiD-CV will save RM35 million (US $10.87 million) and result in 179 more QALYs gained as compared with PCV13 (Table 4) . 
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Cost and Cost-Effectiveness
Based on the estimated incidence, pneumococcal disease would incur a total cost of RM1,403 million (US $435.6 million) per year to the Malaysian health system, as shown in Table 2 . The cost of vaccination, either with PHiD-CV or with PCV13, would incur a cost of RM158.76 million (US $49.3 million) for the study birth cohort, assuming equal costs of RM80 (US $24.84) per dose for PCV13 and PHiD-CV vaccines, respectively. In the absence of vaccination, the health system would incur an undiscounted cost of RM4,858 million (US $1,509 million) for the cohort of 550,000 over the course of their lifetime. With vaccination, direct medical care costs would be reduced by RM93.5 million (US $29 million) for PHiD-CV and by RM55.1 million (US $17.1 million) for PCV13. The majority of the cost saving difference between PHiD-CV and PCV13 is due to the greater reduction in cases of AOM (Table 3) . In terms of cost-effectiveness, PHiD-CV vaccination has a discounted ICER of RM34,328 (US $10,661) per LYG and RM30,290 (US $9,407) per QALY gained compared with a no-vaccination strategy. When comparing against PCV13, PHiD-CV would save discounted costs of RM35 million (US $10.9 million), with 98 fewer discounted life-years, with a discounted ICER of RM359,662 (US $111,696). In contrast, PHiD-CV would gain 179 discounted QALYs compared with PCV13. Therefore, PHiD-CV dominates over PCV13, with an ICER of RMÀ196,618 (US $À61,061) per QALY gained (Table 4) . Because Malaysia's GDP in 2010 was RM28,142 (US $8,740) per capita, the base-case result shows that the PHiD-CV vaccine would be cost-effective for Malaysia on the basis of the World Health Organization threshold of less than three times the per-capita GDP, RM84,426 (US $26,219) per LYG or QALY gained in 2010 [29] . 
Sensitivity Analyses
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Discussion
The results of our study indicate that PHiD-CV is a cost-effective strategy in Malaysia as compared with no vaccination. Similar to previous studies [9, 12, 14, 15] , when comparing PHiD-CV with PCV13, PHiD-CV is advantageous and dominant over PCV13 in terms of QALYs. The QALYs gained are due to its greater effect on the number of AOM cases via its efficacy against NTHi compared with PCV13. In terms of LYG, however, PHiD-CV and PCV13 are virtually identical due to the comparable efficacy of both vaccines on IPD and pneumonia. Although not part of the objectives of this study, a separate analysis of PCV13 versus no vaccination indicates that PCV13 vaccination would be cost-effective over no vaccination. The model used in this study is similar to the one used in a previously published study [15] and it uses local epidemiological inputs derived from a large pool of patient data from four study hospitals as well as local data on serotype coverage.
In the context of the Malaysian health system, the four hospitals in this study are referral centers for the governmentfunded public health system in their respective catchment areas. They are more likely to treat serious cases because such patients would be referred to their care from other public sector facilities within their catchment area. Services in public facilities are fully funded by the government, with a nominal fee charged for most services. Alongside the public system, there also exists in Malaysia a large private health care industry that includes private hospitals that charge market rates for services. Because of their higher cost, private hospitals are concentrated in major cities and treat only 18% of all inpatient cases [30] .
The model used in this study uses the latest efficacy data from multicountry and pivotal clinical trials conducted in populations from Europe and North and South America [17] [18] [19] [20] [21] . The model also follows a birth cohort through the course of its lifetime. Another positive aspect of the model is that it assumes an equal cost for two vaccines, which allows our study to place greater focus on 
efficacy and outcomes rather than price differences, which could be subject to adjustment based on price negotiations. Our study has recognized limitations. First, within the scope of the study, we conducted the analyses for PHiD-CV versus no vaccine and PHiD-CV versus PCV13 only. We did not include the other option of PCV7 in the study. An earlier study [7] had estimated that vaccination with PCV7 of the Malaysian birth cohort would avoid 408 deaths over 10 years compared with no vaccination. PCV7 was estimated to be cost-effective in the Malaysian setting, with an ICER of RM35,196 (US $10,261) per LYG. In comparison, PHiD-CV in the current study has a similar ICER of RM34,328 (US $10,661) per LYG compared with no vaccination, although it should be noted that the two studies were not exactly alike methodologically Because PCV7 is already upgraded to a 13 valent vaccine (PCV13), we did not consider a comparison against PCV7 necessary.
Second, our estimation of disease incidence may have underestimated the number of pneumonia cases because data were collected on the basis of four academic and government hospitals. We may have missed patients who presented with symptoms to other health facilities within or catchment areas around the four study centers, whether private or government. Regarding private hospitals, the numbers of patients presenting to these centers are likely to be small. There are also government facilities within or near the catchment areas that could dilute the patient population presenting to our sites. This is especially true for the two hospitals in the nation's capital, UKM Medical Centre and Hospital Kuala Lumpur. The overall impact of this is that the incidence of disease may have been underestimated, which is not ideal. However, if true disease incidence was actually higher, then the cost-effectiveness of the vaccine would be better than the results we have provided. Hence, despite this limitation, we believe that the results of our study still hold.
The analysis also did not include the cost of vaccine administration. In the analysis comparing PHiD-CV with PCV13, the exclusion has no effect on the ICER because both vaccines would have the same dosing regimen and would incur equal administration cost. For the comparison between PHiD-CV and no vaccination, the addition of administration cost would increase the total cost of the PHiD-CV strategy and consequently increase the ICER of PHiD-CV compared with no vaccination. Administration costs, however, would be relatively low because Malaysia has an existing NIP and vaccination with PHiD-CV would be incorporated into the program.
We acknowledge that several data inputs into the model were obtained from studies on non-Malaysian populations because of the absence of published local data. The effect of PHiD-CV was driven by its impact on AOM, but local epidemiological data were not available for Malaysia. Hence, data from a study within the region were used in the model [16] . Meanwhile, expert panel advice for clinical pathways was used to estimate the number of outpatient visits and determine the cost. Although it would have been preferable to incorporate herd effects and utility weights of disease manifestations from the local population, these were unavailable and inputs were drawn from studies from Canada, the United States, and the United Kingdom [15, [22] [23] [24] . External data were used in the absence of local data because the authors felt that these factors were important and could not be reasonably ignored in the present analysis. Sensitivity analysis indicated that these factors did not alter the conclusions from the basecase result of the study that PCV13 was dominated by PHiD-CV. From our study, the model predicts that PHiD-CV dominates PCV13 with substantial financial savings and higher health gains (measured in QALYs), which is largely due to a larger reduction in AOM. Similar to findings in Australia [9] , the choice would also depend on the burden of AOM, data for which are not currently available for Malaysia. As mentioned, this study used data from a regional study [16] as model inputs because of the scarcity of Malaysian epidemiological estimate of AOM. When life-years are used as the outcome measure, PCV13 is marginally more effective in reducing mortality compared with PHiD-CV, but the 98 life-years difference is based on the entire birth cohort of 550,000 and the additional life-years each come at a cost of RM359,662 (US $111,696). It should also be noted that the model simulated the health and cost effects for a single birth cohort of 550,000 infants and not for all subsequent cohorts as would be the case if pneumococcal vaccine were to be added to the NIP. Given the paucity of local data as discussed above, these findings should be interpreted carefully within the context of a modeling-based analysis and may be revised as more local evidence becomes available. To strengthen the findings of this study, further research should be conducted to obtain the local data inputs related to some aspects of the model such as herd effects, QOL impact of pneumonia and related conditions, and medical utilization in the outpatient setting.
Conclusions
Our results show that PHiD-CV has an ICER that dominates over that of PCV13 at an incremental cost of RMÀ196,618 (US $À61,061) per QALY, as greater QALYs gained with PHiD-CV come at a lower cost. These cost savings from PHiD-CV are driven by a reduction in manifestations and complications of AOM, which result in a much greater benefit over the course of a lifetime of the simulated vaccinated cohort. When compared using LYG, vaccination with PCV13 or PHiD-CV has virtually equal gains in LYG but lower cost with PHiD-CV vaccination at an ICER of RM359,662 (US $111,696) per LYG. Therefore, on the basis of the study results, we conclude that the inclusion of PHiD-CV in the NIP would be cost-effective for Malaysia.
